Naiyer A. Rizvi, MD, of Columbia University, offers an update on immune checkpoint inhibitors in non–small cell lung cancer: what’s new and what’s next.
James L. Mulshine, MD, of Rush University Medical Center, discusses the profound challenges of implementing national CT screening to ensure delivery of high-quality, best-practice early lung cancer detection in the target population of tobacco-exposed individuals (Abstract MS 15.01).
Jennifer King, PhD, of the Lung Cancer Alliance, gives her perspective on major themes of this year’s meeting: the stigma of lung cancer, the changing face of who is affected, early detection, and advances in immunotherapy.
Vassiliki Papadimitrakopoulou, MD, of MD Anderson Cancer Center, discusses the ways in which patients, investigators, and pharmaceutical companies are working together to accelerate research and access to care (Abstract MTE 02.01).
Fred R. Hirsch, MD, PhD, of the University of Colorado Health Science Center, and Paul A. Bunn, Jr, MD, of the University of Colorado Cancer Center, give their views on the goals and important presentations of the 2015 World Conference on Lung Cancer.
Karen Kelly, MD, of the University of California, Davis, summarizes three important papers on NSCLC: expression as a predictive biomarker; pembrolizumab, immune-mediated adverse events, and corticosteroid use; and an evaluation of disease-related symptoms in patients treated with nivolumab or docetaxel (Abstracts ORAL 31.01, 31.02, and 31.03).
